Ask AI
ProCE Banner Activity

HRF-10071: Phase IIa Dose-Ranging, Monotherapy Trial of a Next-generation HIV-1 Maturation Inhibitor in People With HIV Infection

Conference Coverage
Slideset

Varying doses of novel maturation inhibitor HRF-10071 demonstrated a statistically significant reduction in HIV-1 RNA levels vs placebo in treatment-naive people with HIV over a 14-day monotherapy period.

Released: July 18, 2025

Expiration: January 17, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with the International AIDS Society  

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner